Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years.
Read more → 
